Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers
| Status: | Completed |
|---|---|
| Conditions: | Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - 75 |
| Updated: | 4/21/2016 |
| Start Date: | March 2009 |
| End Date: | May 2015 |
A Phase I, Multi-arm, Dose Escalation Study of Brivanib Alaninate Combined With Several Chemotherapy Regimens in Subjects With Solid Tumors
To determine safety and maximum tolerated dose of brivanib alaninate when administered in
combination with capecitabine, doxorubicin, ixabepilone, docetaxel and paclitaxel
chemotherapy to subjects with advanced or metastatic solid tumors
combination with capecitabine, doxorubicin, ixabepilone, docetaxel and paclitaxel
chemotherapy to subjects with advanced or metastatic solid tumors
For more information regarding BMS clinical trial participation, please visit
www.BMSStudyConnect.com.
Inclusion Criteria:
- Histologic/cytologic diagnosis of advanced or metastatic solid tumors
- Life expectancy >= 3 months
- Able to swallow tablets/capsules
Exclusion Criteria:
- Pregnant or breastfeeding women
- No more than 4 previous chemotherapy regimens in the advanced or metastatic setting
(excluding prior adjuvant or hormonal / immuno / biologic antibody therapies
We found this trial at
4
sites
1441 Eastlake Ave
Los Angeles, California 90033
Los Angeles, California 90033
(323) 865-3000
U.S.C./Norris Comprehensive Cancer Center The USC Norris Comprehensive Cancer Center, located in Los Angeles, is...
Click here to add this to my saved trials
Wayne State University Founded in 1868, Wayne State University is a nationally recognized metropolitan research...
Click here to add this to my saved trials
Dana-Farber Cancer Institute Since it’s founding in 1947, Dana-Farber has been committed to providing adults...
Click here to add this to my saved trials